Lv11
20 积分 2023-08-22 加入
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
35分钟前
已完结
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
3小时前
已完结
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
16天前
已完结
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
1个月前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
1个月前
已完结
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
1个月前
已完结
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
1个月前
已完结
Supportive care in cancer—a MASCC perspective
1个月前
已完结
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
